Cabometyx Tablets: Uses, Benefits, Side Effects and Product Information
Description
Cabometyx Tablets – Product Description
Cabometyx is a prescription oncology medicine containing cabozantinib, a targeted therapy classified as a tyrosine kinase inhibitor. It works by blocking specific proteins involved in cancer cell growth, tumour development and the formation of blood vessels that supply tumours.
Cabometyx tablets are used under specialist medical supervision for certain cancers, according to the approved product label in the relevant country. The medicine requires careful monitoring because it can cause serious adverse reactions.
Cordium Pharmaceuticals Pvt Ltd. provides pharmaceutical product information to healthcare professionals, authorised distributors and eligible business partners seeking reliable information about oncology medicines.
Cabometyx Tablets Strengths
Cabometyx tablets are available in the following strengths under the US product label:
Cabometyx 20 mg tablets
Cabometyx 40 mg tablets
Cabometyx 60 mg tablets
Availability, approved indications and marketing authorisation may vary by country. Buyers and healthcare professionals should verify the registered product, manufacturer, packaging and local regulatory requirements before procurement.
Uses and Potential Benefits of Cabometyx
Depending on the applicable approved label, cabozantinib may be prescribed for:
Advanced renal cell carcinoma (RCC): A type of kidney cancer.
Hepatocellular carcinoma (HCC): A type of liver cancer in eligible patients previously treated with sorafenib.
Differentiated thyroid cancer: Certain advanced cases that have progressed following previous targeted treatment.
Pancreatic and extra-pancreatic neuroendocrine tumours: Specific previously treated, unresectable or advanced tumours.
The potential benefit of Cabometyx is its targeted action on pathways associated with tumour growth and progression. Treatment response varies between patients, and the medicine is not a guaranteed cure. An oncologist determines whether it is appropriate based on the diagnosis, previous treatments and individual health factors.
Cabometyx Tablets Side Effects
Common side effects may include:
Diarrhoea, nausea and vomiting
Fatigue and reduced appetite
Weight loss
High blood pressure
Constipation
Mouth inflammation
Hand-foot skin reactions, including redness, pain or peeling
Serious risks: Cabometyx can cause severe bleeding, blood clots, gastrointestinal perforation, liver problems, impaired wound healing and other serious complications. Seek urgent medical attention for severe abdominal pain, significant bleeding, chest pain or sudden difficulty breathing.
Patients should report new or worsening symptoms to their treating doctor. Regular blood pressure checks and laboratory monitoring may be necessary.
Frequently Asked Questions (FAQs)
1. What is Cabometyx used for?
Cabometyx is a targeted cancer medicine prescribed for certain kidney, liver and thyroid cancers and specific neuroendocrine tumours, depending on the approved local label.
2. What are the available Cabometyx strengths?
The US-labelled tablets are available in 20 mg, 40 mg and 60 mg strengths.
3. How should Cabometyx be taken?
Follow the oncologist’s prescription and the local product leaflet. The US label instructs patients to take the tablets on an empty stomach, at least one hour before or two hours after food.
4. Can Cabometyx cause serious side effects?
Yes. Serious bleeding, blood clots, high blood pressure and gastrointestinal complications are possible. Medical supervision is essential.
5. How can buyers enquire about Cabometyx?
Healthcare professionals and authorised pharmaceutical buyers can contact Cordium Pharmaceuticals Pvt Ltd. for product-related enquiries, subject to applicable licensing, availability and regulatory requirements.
Contact Cordium Pharmaceuticals Pvt Ltd.
For Cabometyx product information and pharmaceutical business enquiries, contact Cordium Pharmaceuticals Pvt Ltd. through its official communication channels. Product availability, supply arrangements and export eligibility must be confirmed directly.
